KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
- COVID-19 Currently A Leading Cause of Death Among Children and Young People February 6, 2023A 2021 morbidity study found that COVID-19 was among the leading causes of death in children and young people.
- COVID-19 Omicron Variant Associated with Lower Risk of Severe Illness vs Delta Variant February 6, 2023Vaccination greatly reduces the probability of experiencing severe COVID-19 in both variants. Adults between the ages of 40 to 59 years saw the most significant reduction in risk when compared to individuals in other age categories.
- Patients with COPD and Sleep Apnea See Improved Lung Function with CPAP Compliance February 6, 2023Patients with good continuous positive airway pressure (CPAP) compliance saw improvements in lung function after 12 months, compared to patients with poor CPAP compliance.
- Pharmacy Organizations Partner to Reaffirm Commitment to DEI at All Levels of Health Care February 6, 2023The groups released 8 recommendations to support action across the health care community.
- Is ChatGPT Healthcare's Next Big Thing? February 6, 2023Artificial intelligence has the potential to revolutionize and improve medicine. However, in order for widespread implementation, certain challenges and obstacles must first be overcome.
- FDA Approves Tezepelumab for Self-Administration With New Pre-Filled Pen February 3, 2023After being FDA approved in 2021, tezepelumab (Tezspire) has been approved again for self-administration.
- FDA Approves Sacituzumab Govitecan in Pretreated Metastatic Breast Cancer February 3, 2023Sacituzumab govitecan significantly improved overall survival over the comparator chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer who had received prior treatment.
- News Roundup: January 30 to February 3 February 3, 2023Your weekly roundup of the latest news from Drug Topics®.
- Virtual Care Continues to Evolve into 2023 February 3, 2023The 2022 Virtual Care Survey Report from Summus has determined that many healthcare users have responded positively to virtual care services, as they would like to see more out of such offerings.
- Bills Safety Damar Hamlin Launches #3forHeart CPR Challenge February 2, 2023After an on-field cardiac arrest, Hamlin partnered with the American Heart Association to spotlight the importance of CPR
- Patient Access to Clinical Pharmacists Can Improve Medication Adherence February 6, 2023Data show pharmacist-led clinical consultations can improve patient adherence to medication plans.
- FDA Accepts New Drug Application for New Rapid Treatment for Major Depressive Disorder February 6, 2023The economic burden of symptoms of major depressive disorder were estimated to cost $326 billion for the United States in 2018 alone.
- The Sooner the Better: Why Pharmacies Need a Smarter Pricing System Now February 6, 2023Your pharmacy’s bottom line needs a smarter pricing system to keep up with a tech-smart customer. But when should you make the move?
- ICU Clinical Pharmacists: Helping Preventing Drug-Induced Acute Kidney Injury February 6, 2023The knowledge of clinical pharmacists can help protect kidney function and prevent the development of acute kidney injury in ICU patients.
- Upsher-Smith Opens State-of-the-Art Manufacturing Facility in Maple Grove, Minnesota February 6, 2023
- FDA Approves Prophylaxis Treatment to Prevent Attacks of Hereditary Angioedema in Pediatric Patients February 6, 2023The approval is for the youngest patient population with hereditary angioedema to date.
- Clinical Trial Shows Benefit of Veliparib in ‘BRCA-Like’ Breast Cancer February 6, 2023Patients with triple-negative breast cancer treated with veliparib had statistically significantly longer survival than those given placebo.
- Goals of Treatment for Patients with CP-CML and Acute Phase CML February 6, 2023Brandon Dyson, PharmD, BCOP, BCPS reviews the goals of treatment in chronic myeloid leukemia and Philadelphia chromosome–positive ALL and discusses how the goals differ from acute phase CML.
- FDA Approves Pre-Filled Pen for Self-Administration of Tezepelumab-ekko to Treat Asthma February 6, 2023In a clinical trial program, 92% of health care providers, patients, and caregivers were able to successfully administer tezepelumab-ekko both in the clinic and at home for severe asthma.
- Study Associates High Consumption of Ultra-Processed Food With Risk of Cancer February 6, 2023Ultra-processed food consumption linked to an increased risk of developing and dying from ovarian cancer and breast cancer.
Helping You Navigate the Returns Process!
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at: